Search

Displaying results 1111 - 1120 of 10000 in total
  1. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809] … [L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.

    Synonyms: Clobetasol propionate E, 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionateInternational brands: Embeline E
  2. Target

    Delta(24)-sterol reductase

    go.drugbank.com/bio_entities/BE0014791
    TargetHumans

    Catalyzes the reduction of the delta-24 double bond of sterol intermediates during cholesterol biosynthesis (PubMed:11519011, PubMed:21671375, PubMed:22178193, PubMed:25637936).

    Polypeptides: Delta(24)-sterol reductaseSynonyms: 24-dehydrocholesterol reductase, 3-beta-hydroxysterol Delta-24-reductase
  3. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. … It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.

    Synonyms: N-(n-Butyl)deoxynojirimycin, N-ButylmoranolineProducts: ZAVESCA 100 MG KAPSUL, 84 ADET, ZAVESCA® 100 MG
  4. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC … Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesSynonyms: 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
  5. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863] … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer

    Synonyms: α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrileCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  6. Drug

    Dextromethorphan

    go.drugbank.com/drugs/DB00514
    ApprovedInvestigational

    [A215412] Although similar in structure to other opioids, it has minimal interaction with opioid receptors.[A215412] Dextromethorphan was granted FDA approval before 3 December 1957.

    Mixtures: DAYCOLD-HOT 500/10/15/100 MG SAŞE ,20 SAŞE, DAYCOLD-HOT 500/10/15/100 MG SAŞE ,10 SAŞECategories: Heterocyclic Compounds with 4 or More Rings, Uncompetitive N-methyl-D-aspartate Receptor Antagonist
  7. Drug

    Fibrinogen human

    go.drugbank.com/drugs/DB09222
    ApprovedInvestigational

    It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. … It is indicated for the treatment of acute bleeding episodes in patients with both acquired and congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.[L41065]

    Mixtures: EVICEL Fibrin Sealant (Human) Solution, 50-90 mg/ml, 800-1200 IU/ml, ARTISS 10 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTOR, 1 ADETProducts: VERASEAL SOLUTIONS FOR SEALANT, 80 mg/ml, 500 IU/ml, Haemocomplettan P 1g/2g Pulver zur Herstellung einer Injektions-/Infusionslösung
  8. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    [A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … [L41820] Later, it was approved under a different brand name ZEPBOUND on November 8, 2023, for the chronic weight management in adults with obesity or overweight with at least one weight-related condition

    Categories: Receptors, G-Protein-Coupled, Drugs Used in DiabetesProducts: Mounjaro 10 mg/0,5 ml Enjeksiyonluk Çözelti, 4 ADET, Mounjaro 10 mg solution for injection in vial
  9. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSynonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
  10. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.

    Categories: MATE 2 Inhibitors, MATE 2 SubstratesProducts: UNAMİTY 2 MG FİLM KAPLI TABLET, 56 ADET, UNAMİTY 4 MG FİLM KAPLI TABLET, 56 ADET